PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response
LONDON, Oct. 19, 2020 (GLOBE NEWSWIRE) — PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, today announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine. The study was published on the preprint service bioRxiv website at https://www.biorxiv.org/content/10.1101/2020.10.16.339937v1 and has been submitted for publication in a peer-reviewed journal.
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine
LONDON, June 15, 2020 (GLOBE NEWSWIRE) — Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.